Neumora Therapeutics (NMRA) Competitors $1.38 -0.08 (-5.17%) As of 01:19 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NMRA vs. CMRX, CRON, QURE, OCS, ANAB, BGM, CRMD, VIR, KALV, and AMLXShould you be buying Neumora Therapeutics stock or one of its competitors? The main competitors of Neumora Therapeutics include Chimerix (CMRX), Cronos Group (CRON), uniQure (QURE), Oculis (OCS), AnaptysBio (ANAB), BGM Group (BGM), CorMedix (CRMD), Vir Biotechnology (VIR), KalVista Pharmaceuticals (KALV), and Amylyx Pharmaceuticals (AMLX). These companies are all part of the "pharmaceutical products" industry. Neumora Therapeutics vs. Its Competitors Chimerix Cronos Group uniQure Oculis AnaptysBio BGM Group CorMedix Vir Biotechnology KalVista Pharmaceuticals Amylyx Pharmaceuticals Chimerix (NASDAQ:CMRX) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability. Is CMRX or NMRA more profitable? Chimerix's return on equity of -50.78% beat Neumora Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ChimerixN/A -50.78% -44.94% Neumora Therapeutics N/A -84.79%-77.57% Does the media favor CMRX or NMRA? In the previous week, Neumora Therapeutics had 4 more articles in the media than Chimerix. MarketBeat recorded 4 mentions for Neumora Therapeutics and 0 mentions for Chimerix. Neumora Therapeutics' average media sentiment score of 1.00 beat Chimerix's score of 0.00 indicating that Neumora Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Chimerix Neutral Neumora Therapeutics Positive Do institutionals and insiders hold more shares of CMRX or NMRA? 45.4% of Chimerix shares are held by institutional investors. Comparatively, 47.7% of Neumora Therapeutics shares are held by institutional investors. 13.1% of Chimerix shares are held by insiders. Comparatively, 26.8% of Neumora Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts prefer CMRX or NMRA? Chimerix presently has a consensus price target of $8.53, suggesting a potential downside of 0.08%. Neumora Therapeutics has a consensus price target of $7.14, suggesting a potential upside of 419.48%. Given Neumora Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Neumora Therapeutics is more favorable than Chimerix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Chimerix 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Neumora Therapeutics 1 Sell rating(s) 5 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.22 Which has more volatility & risk, CMRX or NMRA? Chimerix has a beta of -0.17, suggesting that its stock price is 117% less volatile than the S&P 500. Comparatively, Neumora Therapeutics has a beta of 2.75, suggesting that its stock price is 175% more volatile than the S&P 500. Which has preferable valuation & earnings, CMRX or NMRA? Chimerix has higher revenue and earnings than Neumora Therapeutics. Chimerix is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioChimerix$212K3,778.71-$82.10M-$0.99-8.63Neumora TherapeuticsN/AN/A-$243.79M-$1.61-0.85 SummaryNeumora Therapeutics beats Chimerix on 9 of the 14 factors compared between the two stocks. Get Neumora Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NMRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NMRA vs. The Competition Export to ExcelMetricNeumora TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$222.41M$2.92B$5.56B$9.30BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-0.8520.3528.6119.64Price / SalesN/A304.32437.49188.30Price / CashN/A43.1536.0257.93Price / Book0.777.718.185.63Net Income-$243.79M-$55.11M$3.23B$257.73M7 Day Performance34.80%0.68%-0.25%0.07%1 Month Performance59.22%8.22%5.40%8.32%1 Year Performance-88.43%-2.64%26.35%13.78% Neumora Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NMRANeumora Therapeutics2.7245 of 5 stars$1.38-5.2%$7.14+419.5%-87.5%$222.41MN/A-0.85108News CoveragePositive NewsAnalyst ForecastGap UpCMRXChimerix0.549 of 5 stars$8.54flat$8.53-0.1%N/A$801.09M$212K-9.0990CRONCronos Group1.5795 of 5 stars$2.07-1.0%N/A-15.1%$798.36M$117.61M15.92450QUREuniQure2.6993 of 5 stars$14.55+1.0%$37.82+159.9%+53.2%$797.05M$27.12M-3.31500OCSOculis2.0552 of 5 stars$18.16+0.6%$35.33+94.6%+53.7%$792.90MN/A-6.882ANABAnaptysBio1.6589 of 5 stars$26.95+2.9%$42.38+57.2%-18.6%$791.79M$91.28M-5.56100BGMBGM GroupN/A$8.08-13.2%N/AN/A$785.54M$25.10M0.00298CRMDCorMedix2.6776 of 5 stars$11.36+1.2%$17.14+50.9%+132.0%$770.49M$82.55M51.6430VIRVir Biotechnology3.5628 of 5 stars$5.50-2.7%$30.25+450.0%-44.6%$760.32M$74.21M-1.30580KALVKalVista Pharmaceuticals4.0343 of 5 stars$15.22+4.8%$26.29+72.7%+1.4%$760.24MN/A-4.12100Earnings ReportAnalyst RevisionAMLXAmylyx Pharmaceuticals3.3839 of 5 stars$8.41+9.5%$11.75+39.7%+275.9%$749.68M-$1.27M-2.70200High Trading Volume Related Companies and Tools Related Companies Chimerix Competitors Cronos Group Competitors uniQure Competitors Oculis Competitors AnaptysBio Competitors BGM Group Competitors CorMedix Competitors Vir Biotechnology Competitors KalVista Pharmaceuticals Competitors Amylyx Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NMRA) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDrilling With a $3.5B Discovery Partner in Its CornerA small-cap explorer is about to drill for high-grade gold in a region known for multi-million-ounce discoveri...The Tomorrow Investor | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neumora Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neumora Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NMRA Stock Alerts